Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 28 (7), 583-9

Ketorolac 0.45% Ophthalmic Solution

Affiliations
Review

Ketorolac 0.45% Ophthalmic Solution

Paul L McCormack. Drugs Aging.

Abstract

Ketorolac 0.45% ophthalmic solution is a topical NSAID indicated in the US for the treatment of ocular pain and inflammation following cataract surgery. In animal studies, the ocular relative bioavailability of single-dose topical ketorolac 0.45% ophthalmic solution was 2- to 3-fold higher than that of ketorolac 0.4% ophthalmic solution. In two identically designed, randomized, double-masked, multicentre trials in adult patients undergoing cataract extraction, the proportions of patients with a summed ocular inflammation score of zero for anterior chamber cell count plus anterior chamber flare on day 14 after surgery were significantly greater in those treated with topical ketorolac 0.45% ophthalmic solution than in those treated with vehicle placebo. Compared with placebo, topical ketorolac 0.45% ophthalmic solution significantly increased the proportion of patients who were pain-free on the day after surgery in both trials. Ketorolac 0.45% ophthalmic solution was generally well tolerated in clinical trials with lower overall incidences of treatment-emergent and treatment-related adverse events than placebo, and with no single treatment-related adverse event having a higher incidence than with placebo.

Similar articles

See all similar articles

Cited by 5 PubMed Central articles

References

    1. J Cataract Refract Surg. 1999 May;25(5):699-704 - PubMed
    1. Am J Ophthalmol. 2010 May;149(5):777-84 - PubMed
    1. J Cataract Refract Surg. 2002 Jan;28(1):93-9 - PubMed
    1. J Ocul Pharmacol Ther. 2011 Apr;27(2):173-8 - PubMed
    1. Am J Ophthalmol. 2011 Mar;151(3):420-6.e1 - PubMed

MeSH terms

Substances

LinkOut - more resources

Feedback